Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Simmler, L
Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously
But if we keep eating the same food, we get fewer nutrients and become dependent on these drugs
Research conducted by Khavinson and colleagues demonstrated that Epithalon could increase the lifespan of mammalian cells through telomerase activation
US$ 27.51
US$ 24.59
US$ 20.21
US$ 26.13
US$ 23.11
US$ 25.57
